Form 4: Catalyst Pharmaceuticals Executive Ingenito Reports Stock Transactions

Gary Ingenito, Chief Medical and Regulatory Officer at Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• Gary Ingenito, Chief Medical and Regulatory Officer of Catalyst Pharmaceuticals, filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On December 9, 2024, 7,349 restricted stock units vested, converting into common stock.
• A total of 2,891 shares were withheld to cover tax obligations related to the vesting.
• Following these transactions, Ingenito directly owns 55,849 shares of common stock and 1,034,282 restricted stock units.
• The restricted stock units vest in three equal tranches, with the first tranche vesting on December 8, 2024, and the remaining tranches vesting on December 8, 2025 and December 8, 2026.

Sentiment

Score: 7

Explanation: The document is a routine filing related to executive compensation, indicating a neutral to slightly positive sentiment as it reflects the execution of a pre-existing compensation plan.

Industry Context

This is a routine filing related to executive compensation and is common in the pharmaceutical industry.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the pharmaceutical industry to align executive interests with shareholder value.
• The vesting schedule of the restricted stock units is typical for executive compensation packages.
• Tax withholding on vesting is a standard procedure.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it is related to executive compensation.
• The vesting of restricted stock units is part of the executive's compensation package.

Key Dates

Keywords

Form 4, Catalyst Pharmaceuticals, stock transaction, restricted stock units, insider trading, beneficial ownership, vesting, tax withholding